Computational Models for Predicting the Binding Affinities of Ligands for the Wild-Type Androgen Receptor and a Mutated Variant Associated with Human Prostate Cancer

Chemical Research in Toxicology

Volumn 16, Issue 12, 2003, Pages 1652-1660

  Ai, Ni ^a   DeLisle, Robert K ^b   Yu, Seong Jae ^a,c   Welsh, William J ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b PHARMACOPEIA INC   (United States)

^c FMC CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHYLENE; ANDROGEN RECEPTOR; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTENEDIONE; CHLORPHENOTANE; CORTICOSTERONE; DIETHYLSTILBESTROL; ESTRADIOL; HYDROCORTISONE; HYDROXYFLUTAMIDE; HYDROXYLINURON; HYDROXYPOLYCHLORINATED BIPHENYL 153; HYDROXYPROGESTERONE; LIGAND; LINURON; METHOXYCHLOR; METRIBOLONE; MIBOLERONE; MUTANT PROTEIN; ORGANOPHOSPHATE PESTICIDE; POLYCHLORINATED BIPHENYL 153; PREGNENOLONE; PROGESTERONE; STEROID; TESTOSTERONE; UNCLASSIFIED DRUG; VINCLOZOLIN;

ARTICLE; BINDING AFFINITY; COMPARATIVE MOLECULAR FIELD ANALYSIS; CORRELATION ANALYSIS; ELECTROCHEMISTRY; HORMONE RECEPTOR INTERACTION; HUMAN; MATHEMATICAL MODEL; PREDICTION; PROSTATE CANCER; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY; WILD TYPE;

AMINO ACID SUBSTITUTION; ANIMALS; HUMANS; KINETICS; LIGANDS; MALE; MODELS, BIOLOGICAL; MODELS, CHEMICAL; PROSTATIC NEOPLASMS; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RECEPTORS, ANDROGEN; THERMODYNAMICS;

EID: 0345737133     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx034168k     Document Type: Article

References (47)

1. Whitfield, G. K., Jurutka, P. W., Haussler, C. A., and Haussler, M. R. (1999) Steroid hormone receptors: evolution, ligands, and molecular basis of biologic function. J. Cell. Biochem. Suppl. 110-122.
2. Tenbaum, S., and Baniahmad, A. (1997) Nuclear receptors: structure, function and involvement in disease. Int. J. Biochem. Cell Biol. 29, 1325-1341.
3. Avila, D. M., Zoppi, S., and McPhaul, M. J. (2001) The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer. J. Steroid Biochem. Mol. Biol. 76, 135-142.
4. Steketee, K., Timmerman, L., Ziel-van der Made, A. C., Doesburg, P., Brinkmann, A. O., and Trapman, J. (2002) Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int. J. Cancer 100, 309-317.
5. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398.
6. Taplin, M. E., Bubley, G. J., Ko, Y. J., Small, E. J., Upton, M., Rajeshkumar, B., and Balk, S. P. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 59, 2511-2515.
7. Kokontis, J., Ito, K., Hiipakka, R. A., and Liao, S. (1991) Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. Receptor 1, 271-279.
8. Fry, D. M. (1995) Reproductive effects in birds exposed to pesticides and industrial chemicals. Environ. Health Perspect. 103, 165-171.
9. Gray, L. E., Ostby, J., Furr, J., Wolf, C. J., Lambright, C., Parks, L., Veeramachaneni, D. N., Wilson, V., Price, M., Hotchkiss, A., Orlando, E., and Guillette, L. (2001) Effects of environmental antiandrogens on reproductive development in experimental animals. Hum. Reprod. Update 7, 248-264.
10. Crews, D., Willingham, E., and Skipper, J. K. (2000) Endocrine disruptors: present issues, future directions. Q. Rev. Biol. 75, 243-260.
11. Tamura, H., Yoshikawa, H., Gaido, K. W., Ross, S. M., DeLisle, R. K., Welsh, W. J., and Richard, A. M. (2003) Interaction of Organophosphate Pesticides and Related Compounds with the Androgen Receptor. Environ. Health Perspect. 111, 545-552.
12. Kelce, W. R., Lambright, C. R., Gray, L. E., Jr., and Roberts, K. P. (1997) Vinclozolin and p,p′-DDE alter androgen-dependent gene expression: in vivo confirmation of an androgen receptor-mediated mechanism. Toxicol. Appl. Pharmacol. 142, 192-200.
13. Kelce, W. R., and Wilson, E. M. (1997) Environmental antiandrogens: developmental effects, molecular mechanisms, and clinical implications. J. Mol. Med. 75, 198-207.
14. Sack, J. S., Kish, K. F., Wang, C., Attar, R. M., Kiefer, S. E., An, Y., Wu, G. Y., Scheffler, J. E., Salvati, M. E., Krystek, S. R., Jr., Weinmann, R., and Einspahr, H. M. (2001) Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 98, 4904-4909.
15. Waller, C. L., Juma, B. W., Gray, L. E., Jr., and Kelce, W. R. (1996) Three-dimensional quantitative structure-activity relationships for androgen receptor ligands. Toxicol. Appl. Pharmacol. 137, 219-227.
16. Tong, W., Perkins, R., Xing, L., Welsh, W. J., and Sheehan, D. M. (1997) QSAR models for binding of estrogenic compounds to estrogen receptor alpha and beta subtypes. Endocrinology 138, 4022-4025.
17. Tong, W., Perkins, R., Strelitz, R., Collantes, E. R., Keenan, S., Welsh, W. J., Branham, W. S., and Sheehan, D. M. (1997) Quantitative structure-activity relationships (QSARs) for estrogen binding to the estrogen receptor: predictions across species. Environ. Health Perspect. 105, 1116-1124.
18. Tong, W., Lowis, D. R., Perkins, R., Chen, Y., Welsh, W. J., Goddette, D. W., Heritage, T. W., and Sheehan, D. M. (1998) Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor. J. Chem. Inf. Comput. Sci. 38, 669-677.
19. Xing, L., Welsh, W. J., Tong, W., Perkins, R., and Sheehan, D. M. (1999) Comparison of estrogen receptor alpha and beta subtypes based on comparative molecular field analysis (CoMFA). SAR QSAR Environ. Res. 10, 215-237.
20. Yu, S. J., Keenan, S. M., Tong, W., and Welsh, W. J. (2002) Influence of the structural diversity of data sets on the statistical quality of three-dimensional quantitative structure-activity relationship (3D-QSAR) models: predicting the estrogenic activity of xenoestrogens. Chem. Res. Toxicol. 15, 1229-1234.
21. Fang, H., Tong, W., Welsh, W. J., and Sheehan, D. M. (2003) QSAR models in receptor-mediated effects: The nuclear receptor superfamily. J. Mol. Struct. (THEOCHEM) 622, 113-125.
22. Taplin, M. E., and Ho, S. M. (2001) Clinical review 134: The endocrinology of prostate cancer. J. Clin. Endocrinol. Metab. 86, 3467-3477.
23. Huang, H., and Tindall, D. J. (2002) The role of the androgen receptor in prostate cancer. Crit. Rev. Eukaryotic Gene Expression 12, 193-207.
24. Berrevoets, C. A., Umar, A., and Brinkmann, A. O. (2002) Antiandrogens: selective androgen receptor modulators. Mol. Cell Endocrinol. 198, 97-103.
25. Buchanan, G., Greenberg, N. M., Scher, H. I., Harris, J. M., Marshall, V. R., and Tilley, W. D. (2001) Collocation of androgen receptor gene mutations in prostate cancer. Clin. Cancer Res. 7, 1273-1281.
26. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C., Trapman, J., Brinkmann, A. O., and Mulder, E. (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem. Biophys. Res. Commun. 173, 534-540.
27. Wold, S., Albano, C., Dunn, W. I., Edlund, U., Esbensen, K., Geladi, P., Hellberg, S. E. J., Lindberg, W., and Sjostrom, M. (1984) In Chemometrics: Mathematics and Statistics in Chemistry (Kowalski, B., Ed.) Reidel, Dordrecht, The Netherlands.
28. Cramer, R. D., 3rd, Patterson, D. E., and Bunce, J. D. (1989) Recent advances in comparative molecular field analysis (CoMFA). Prog. Clin. Biol. Res. 291, 161-165.
29. Jain, A. K., Duin, R. P. W., and Mao, J. (2000) Statistical pattern recognition: A review. IEEE Trans. Pattern Anal. Machine Intelligence 22, 4-37.
30. Zhao, X. Y., Malloy, P. J., Krishnan, A. V., Swami, S., Navone, N. M., Peehl, D. M., and Feldman, D. (2000) Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 6, 703-706.
31. Chang, C. Y., Walther, P. J., and McDonnell, D. P. (2001) Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res. 61, 8712-8717.
32. Oh, W. K. (2002) Secondary hormonal therapies in the treatment of prostate cancer. Urology 60, 87-92; discussion 93.
33. Marks, L. S., DiPaola, R. S., Nelson, P., Chen, S., Heber, D., Belldegrun, A. S., Lowe, F. C., Fan, J., Leaders, F. E., Jr., Pantuck, A. J., and Tyler, V. E. (2002) PC-SPES: herbal formulation for prostate cancer. Urology 60, 369-375; discussion 376-367.
34. Rafi, M. M., Vastano, B. C., Zhu, N., Ho, C. T., Ghai, G., Rosen, R. T., Gallo, M. A., and DiPaola, R. S. (2002) Novel polyphenol molecule isolated from licorice root (Glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. J. Agric. Food Chem. 50, 677-684.
35. Gaido, K. W., Maness, S. C., McDonnell, D. P., Dehal, S. S., Kupfer, D., and Safe, S. (2000) Interaction of methoxychlor and related compounds with estrogen receptor alpha and beta, and androgen receptor: structure-activity studies. Mol. Pharmacol. 58, 852-858.
36. Negro-Vilar, A. (1999) Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J. Clin. Endocrinol. Metab. 84, 3459-3462.
37. Yin, D., He, Y., Perera, M. A., Hong, S. S., Marhefka, C., Stourman, N., Kirkovsky, L., Miller, D. D., and Dalton, J. T. (2003) Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol. Pharmacol. 63, 211-223.
38. Yin, D., Gao, W., Kearbey, J. D., Xu, H., Chung, K., He, Y., Marhefka, C. A., Veverka, K. A., Miller, D. D., and Dalton, J. T. (2003) Pharmacodynamics of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. 304, 1334-1340.
39. DeLisle, R. K., Yu, S. J., Nair, A. C., and Welsh, W. J. (2001) Homology modeling of the estrogen receptor subtype beta (ER-beta) and calculation of ligand binding affinities. J. Mol. Graphics Modell. 20, 155-167.
40. Jayatilleke, P. R., Nair, A. C., Zauhar, R., and Welsh, W. J. (2000) Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. J. Med. Chem. 43, 4446-4451.
41. Nair, A. C., Jayatilleke, P., Wang, X., Miertus, S., and Welsh, W. J. (2002) Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties. J. Med. Chem. 45, 973-983.
42. Puri, S., Chickos, J. S., and Welsh, W. J. (2002) Three-dimensional quantitative structure-property relationship (3D-QSPR) models for prediction of thermodynamic properties of polychlorinated biphenyls (PCBs): enthalpy of vaporization. J. Chem. Inf. Comput. Sci. 42, 299-304.
43. Puri, S., Chickos, J. S., and Welsh, W. J. (2002) Three-dimensional quantitative structure-property relationship (3D-QSPR) models for prediction of thermodynamic properties of polychlorinated biphenyls (PCBs): enthalpy of sublimation. J. Chem. Inf. Comput. Sci. 42, 109-116.
44. Puri, S., Chickos, J. S., and Welsh, W. J. (2003) Three-dimensional quantitative structure-property relationship (3D-QSPR) models for prediction of thermodynamic properties of polychlorinated biphenyls (PCBs): enthalpies of fusion and their application to estimates of enthalpies of sublimation and aqueous solubilities. J. Chem. Inf. Comput. Sci. 43, 55-62.
45. McDonald, S., Brive, L., Agus, D. B., Scher, H. I., and Ely, K. R. (2000) Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res. 60, 2317-2322.
46. Wang, C., Young, W. J., and Chang, C. (2000) Isolation and characterization of the androgen receptor mutants with divergent transcriptional activity in response to hydroxyflutamide. Endocrine 12, 69-76.
47. Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., Basler, S., Schafer, M., Egner, U., and Carrondo, M. A. (2000) Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 275, 26164-26171.